- Home
- ETV vs MESO Comparison
ETV vs MESO Comparison
Compare ETV & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETV
- MESO
- Stock Information
- Founded
- ETV 2005
- MESO 2004
- Country
- ETV United States
- MESO Australia
- Employees
- ETV N/A
- MESO N/A
- Industry
- ETV Investment Managers
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETV Finance
- MESO Health Care
- Exchange
- ETV Nasdaq
- MESO Nasdaq
- Market Cap
- ETV 1.4B
- MESO 1.4B
- IPO Year
- ETV N/A
- MESO N/A
- Fundamental
- Price
- ETV $13.19
- MESO $10.97
- Analyst Decision
- ETV
- MESO Buy
- Analyst Count
- ETV 0
- MESO 4
- Target Price
- ETV N/A
- MESO $18.00
- AVG Volume (30 Days)
- ETV 252.5K
- MESO 163.9K
- Earning Date
- ETV 01-01-0001
- MESO 02-26-2025
- Dividend Yield
- ETV 8.75%
- MESO N/A
- EPS Growth
- ETV N/A
- MESO N/A
- EPS
- ETV N/A
- MESO N/A
- Revenue
- ETV N/A
- MESO $5,670,000.00
- Revenue This Year
- ETV N/A
- MESO $152.37
- Revenue Next Year
- ETV N/A
- MESO $336.12
- P/E Ratio
- ETV N/A
- MESO N/A
- Revenue Growth
- ETV N/A
- MESO N/A
- 52 Week Low
- ETV $11.05
- MESO $5.78
- 52 Week High
- ETV $13.50
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- ETV 57.05
- MESO 44.34
- Support Level
- ETV $12.98
- MESO $10.77
- Resistance Level
- ETV $13.28
- MESO $11.61
- Average True Range (ATR)
- ETV 0.20
- MESO 0.47
- MACD
- ETV 0.09
- MESO 0.09
- Stochastic Oscillator
- ETV 93.33
- MESO 27.68
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.